

CITATION REPORT

List of articles citing

A novel panel of blood markers to assess the degree of liver fibrosis

DOI: 10.1002/hep.20935
Hepatology, 2005, 42, 1373-81.

Source: <https://exaly.com/paper-pdf/38330066/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
450	[Noninvasive assessment of liver fibrosis in patients with chronic hepatitis virus C]. 2006 , 35, 1317-26		2
449	[Serum markers of non-invasive fibrosis in chronic hepatitis C virus infection]. <i>Revue De Medecine Interne</i> , 2006 , 27, 751-61	0.1	5
448	Current World Literature. 2006 , 11, 311-350		
447	Noninvasive diagnosis of liver fibrosis by ultrasonic transient elastography (Fibroscan). <i>European Journal of Gastroenterology and Hepatology</i> , 2006 , 18, 1321-5	2.2	53
446	Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. 2006 , 6, 34		199
445	Noninvasive ratio indexes to evaluate fibrosis staging in chronic hepatitis C: role of platelet count/spleen diameter ratio index. 2006 , 260, 142-50		31
444	Transient elastography: a valid alternative to biopsy in patients with chronic liver disease. 2006 , 24, 513-8		84
443	Fibrosis markers in hepatitis C. 2006 , 5, 86-93		2
442	[Liver biopsy in management of chronic liver diseases: "EASL monothematic conference highlights"]. 2006 , 30, 121-3		1
441	Noninvasive markers of fibrosis in chronic hepatitis patients. 2006 , 40, 461-3		2
440	Noninvasive tests for liver fibrosis. 2006 , 26, 337-47		13
439	Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. 2007 , 53, 1615-22		208
438	The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. 2007 , 97, 582-94		13
437	Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C. 2007 , 41, 616-23		155
436	Exploration biologique h�patique. 2007 , 2, 1-6		2
435	Conduite �tenir devant une �vation des gamma-glutamyl-transff�ases. 2007 , 2, 1-5		1
434	[Results and place of Fibroscan in the non-invasive diagnosis of hepatic fibrosis]. <i>Revue De Medecine Interne</i> , 2007 , 28, 94-102	0.1	6

433	Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. 2007 , 381, 107-13		151
432	Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. 2007 , 46, 395-402		106
431	In the new area of noninvasive markers of hepatocellular carcinoma. 2007 , 46, 9-11		13
430	Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. 2007 , 46, 775-82		180
429	Non-invasive tests for liver fibrosis: encouraging or discouraging results?. 2007 , 46, 751-5		28
428	[Noninvasive markers of fibrosis: replacement for liver biopsy?]. 2007 , 36, 453-5		
427	[Noninvasive methods for predicting liver fibrosis in patients with chronic hepatitis C: alternatives to liver biopsy]. 2007 , 36, 457-66		3
426	FibroMAX: towards a new universal biomarker of liver disease?. 2007 , 7, 481-90		43
425	FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. 2007 , 102, 2589-600		297
424	FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. <i>Hepatology</i> , 2007 , 45, 297-306	11.2	201
423	FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. <i>Hepatology</i> , 2007 , 46, 32-6	11.2	1222
422	Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. <i>Hepatology</i> , 2007 , 46, 912-21	11.2	313
421	FibroTest has better diagnostic and prognostic values than the aspartate aminotransferase-to-platelet ratio index in patients with chronic hepatitis C. <i>Hepatology</i> , 2008 , 47, 353-4; author reply 354-6	11.2	16
420	Meta-analyses of FibroTest diagnostic value in chronic liver disease. 2007 , 7, 40		223
419	Évaluation Non Invasive de la Fibrose Hépatique au Cours des Hépatites Chroniques Virales C. 2007 , 2007, 33-40		
418	Improving estimation of liver fibrosis using combination and newer noninvasive biomarker scoring systems in hepatitis C-infected haemophilia patients. 2007 , 13, 722-9		14
417	Epidemiology of chronic hepatitis B infection in France: risk factors for significant fibrosis--results of a nationwide survey. 2007 , 26, 565-76		28
416	Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis. <i>Liver International</i> , 2007 , 27, 639-45	7.9	56

415	Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality. 2007 , 11, 1031-51		75
414	[Why and how to evaluate liver fibrosis in 2007]. 2007 , 31, 501-3		
413	[Characteristics and interpretation of blood tests for liver fibrosis]. 2007 , 31, 511-23; quiz 500, 531-2		4
412	Utilisation des marqueurs non invasifs de fibrose dans la prise en charge de l'hépatite C. 2007 , 31, 34-39		1
411	Évaluation non invasive de la fibrose hépatique au cours des co-infections VIH et VHC et/ou VHB. 2007 , 1, 54-58		
410	Reproducibility of blood tests of liver fibrosis in clinical practice. 2008 , 41, 10-8		57
409	Liver biopsy versus noninvasive testing in chronic hepatitis C: Where do we stand in 2008?. 2008 , 7, 51-59		1
408	Noninvasive assessment of liver fibrosis in chronic hepatitis C infection. 2008 , 7, 164-172		
407	Recent advances in the pathogenesis and diagnosis of liver fibrosis. 2008 , 43, 315-21		46
406	Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. <i>Hepatology</i> , 2008 , 47, 789-98	11.2	139
405	The future is around the corner: Noninvasive diagnosis of progressive nonalcoholic steatohepatitis. <i>Hepatology</i> , 2008 , 47, 373-5	11.2	28
404	Reproducibility of non-invasive fibrosis biomarkers, FibroMeter and FibroTest, could be improved by respecting the analytical standardizations. 2008 , 41, 1113-4		5
403	Diagnostic accuracy, reproducibility and robustness of fibrosis blood tests in chronic hepatitis C: a meta-analysis with individual data. 2008 , 41, 1368-76		57
402	Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C. <i>Liver International</i> , 2008 , 28, 1352-62	7.9	82
401	Noninvasive markers of liver fibrosis: playing the probabilities. <i>Liver International</i> , 2008 , 28, 1328-31	7.9	4
400	Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. 2008 , 28, 2-12		114
399	Optimized stepwise combination algorithms of non-invasive liver fibrosis scores including Hepascore in hepatitis C virus patients. 2008 , 28, 458-67		47
398	Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan: prospective comparison with seven non-invasive laboratory tests. 2008 , 28, 1188-98		160

397	Discordance between biochemical markers of liver activity and fibrosis (Actitest-Fibrotest) and liver biopsy in patients with chronic hepatitis C. 2008 , 32, 858-65	9
396	Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests. 2008 , 32, 1050-60	11
395	[Non-invasive evaluation of liver fibrosis in hepatitis C]. 2008 , 32, S90-5	7
394	Diagnosis of liver fibrosis in 2008. 2008 , 32, 1-3	2
393	FibroTest-ActiTest as a non-invasive marker of liver fibrosis. 2008 , 32, 22-39	84
392	FibroMeters: a family of blood tests for liver fibrosis. 2008 , 32, 40-51	36
391	Combining non-invasive methods for assessment of liver fibrosis. 2008 , 32, 73-9	11
390	Noninvasive assessment of liver fibrosis: serum markers, imaging, and other modalities. 2008 , 12, 883-900, x	29
389	Biomarcadores de fibrosis hepática. 2008 , 7, 280-284	
388	¹³ C-methacetin-breath test compared to also noninvasive biochemical blood tests in predicting hepatic fibrosis and cirrhosis in chronic hepatitis C. 2008 , 40, 743-8	27
387	Genesis of hepatic fibrosis and its biochemical markers. 2008 , 68, 260-9	30
386	Actualité sur les co-infections VIH/HCV. 2008 , 10, 167-175	
385	Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography. 2008 , 5, 95-106	133
384	Clinical applicability of non-invasive markers for liver fibrosis in chronic hepatitis C. 2008 , 48, 882-884	
383	Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study--ANRS HC02. 2008 , 48, 765-73	75
382	Automated assay of hyaluronic acid in serum. 2008 , 23, 148-152	3
381	Non-invasive markers for the prediction of fibrosis in chronic hepatitis C infection. 2008 , 38, 762-9	8
380	Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C. 2008 , 6, 242-7	50

379	A clinical and histopathologic perspective on evolving noninvasive and invasive alternatives for liver biopsy. 2008 , 6, 491-6		8
378	Reproducibility of liver stiffness measurement by ultrasonographic elastometry. 2008 , 6, 1263-9		97
377	Liver fibrosis. 2008 , 411, 1-18		249
376	Usefulness of six non-proprietary indirect markers of liver fibrosis in patients with chronic hepatitis C. 2008 , 46, 253-9		8
375	Assessing liver fibrosis. 2008 , 2, 541-52		31
374	Biomarkers of liver fibrosis. 2008 , 46, 131-60		50
373	Expression of defective hepatitis B virus particles derived from singly spliced RNA is related to liver disease. 2008 , 198, 218-25		42
372	Learning curve and interobserver reproducibility evaluation of liver stiffness measurement by transient elastography. <i>European Journal of Gastroenterology and Hepatology</i> , 2008 , 20, 693-701	2.2	79
371	Fiber evanescent wave spectroscopy using the mid-infrared provides useful fingerprints for metabolic profiling in humans. 2009 , 14, 054033		40
370	Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection. 2009 , 200, 1774-80		92
369	Can nonalcoholic steatohepatitis be diagnosed without liver biopsy?. 2009 , 3, 353-61		4
368	Non-invasive assessment of liver fibrosis in chronic liver diseases: implementation in clinical practice and decisional algorithms. <i>World Journal of Gastroenterology</i> , 2009 , 15, 2190-203	5.6	62
367	A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease. 2009 , 9, 271		59
366	[Non-invasive diagnosis of liver fibrosis: guidelines for the use of biomarkers and FibroScan]. 2009 , 33, 334-44		6
365	The risks of changing the rules for previously validated biomarkers and using the same patients several times. Response letter to Calz et al. <i>Gastroenterol Clin Biol</i> 2008;32:1050-60: "Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests". 2009 , 33, 387-8; author reply 388-9		
364	Which would you prefer for a liver fibrosis test: A limited fixed menu or a gourmet buffet?. 2009 , 33, 388-389		
363	[Alcohol and the liver]. 2009 , 33, 840-9		3
362	Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. <i>Hepatology</i> , 2009 , 49, 97-105	11.2	196

361	Liver biopsy findings in chronic hepatitis B. <i>Hepatology</i> , 2009 , 49, S61-71	11.2	83
360	Prospective validation of a noninvasive index for predicting liver fibrosis in hepatitis C virus-infected liver transplant recipients. 2009 , 15, 1798-807		16
359	Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). 2009 , 3, 323-33		73
358	Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C. 2009 , 30, 557-76		102
357	Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. 2009 , 16, 203-13		37
356	Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. 2009 , 16, 300-14		127
355	Assessment of fibrosis in chronic liver diseases. 2009 , 10, 7-14		38
354	Syndecan 1 (CD138) serum levels: a novel biomarker in predicting liver fibrosis stage in patients with hepatitis C. <i>Liver International</i> , 2009 , 29, 208-12	7.9	15
353	The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis. <i>Liver International</i> , 2009 , 29, 1507-15	7.9	94
352	Analogues and fibrosis regression in hepatitis B. 2009 , 33, 923-9		6
351	[FibroMeters: a family of blood tests for liver fibrosis with high diagnostic performance and applicability in clinical practice]. 2009 , 57, 459-62		2
350	Comparison of blood tests for liver fibrosis specific or not to NAFLD. 2009 , 50, 165-73		195
349	Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients. 2009 , 50, 1074-83		56
348	Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. 2009 , 7, 1224-9, 1229.e1-2		207
347	Nonalcoholic fatty liver disease: a practical approach to evaluation and management. 2009 , 13, 249-66		48
346	Novel serum markers of fibrosis progression for the follow-up of hepatitis C virus-infected patients. 2009 , 175, 46-53		20
345	Validation of hepascore, compared with simple indices of fibrosis, in patients with chronic hepatitis C virus infection in United States. 2009 , 7, 696-701		57
344	Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. 2009 , 7, 219-26		39

343	Treatment of liver fibrosis: clinical aspects. 2009 , 33, 958-66		7
342	Noninvasive assessment of fibrosis and steatosis in NASH and ASH. 2009 , 33, 940-8		12
341	Hepatitis C virus: a critical appraisal of approaches to therapy. 2009 , 7, 397-414; quiz 366		16
340	Accuracy of simple biochemical tests in identifying liver fibrosis in patients co-infected with human immunodeficiency virus and hepatitis C virus. 2009 , 7, 339-45		32
339	Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , 2009 , 21, 28-38	2.2	51
338	Virus de l'hépatite B. 2010 , 5, 1-11		
337	Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy. <i>European Journal of Gastroenterology and Hepatology</i> , 2010 , 22, 474-80	2.2	26
336	Acoustic radiation force impulse: a new ultrasonographic technology for the widespread noninvasive diagnosis of liver fibrosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2010 , 22, 1074-84	2.2	113
335	Assessment of allograft fibrosis by transient elastography and noninvasive biomarker scoring systems in liver transplant patients. 2010 , 89, 983-93		59
334	Perspectives on fibrosis progression in hepatitis C: an à la carte approach to risk factors and staging of fibrosis. <i>Antiviral Therapy</i> , 2010 , 15, 281-91	1.6	16
333	Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use. <i>Antiviral Therapy</i> , 2010 , 15, 963-74	1.6	27
332	Non-invasive test of liver fibrosis for the diagnosis of oesophageal varices in patients with chronic liver disease or portal vein thrombosis. 2010 ,		4
331	Fatty liver disease in children: eat now pay later. 2010 , 4, 375-85		23
330	External validation of P2/MS and comparison with other simple non-invasive indices for predicting liver fibrosis in HBV-infected patients. 2010 , 55, 2636-43		5
329	Evaluation of FibroTest-ActiTest in children with chronic hepatitis C virus infection. 2010 , 34, 16-22		19
328	Optimization and robustness of blood tests for liver fibrosis and cirrhosis. 2010 , 43, 1315-22		38
327	Novel biomarkers predict liver fibrosis in hepatitis C patients: alpha 2 macroglobulin, vitamin D binding protein and apolipoprotein AI. 2010 , 17, 58		61
326	Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. 2010 , 10, 103		92

325	Noninvasive diagnosis of large esophageal varices by Fibroscan: strong influence of the cirrhosis etiology. 2010 , 34, 1146-53		26
324	Diagnosis of different liver fibrosis characteristics by blood tests in non-alcoholic fatty liver disease. <i>Liver International</i> , 2010 , 30, 1346-54	7.9	35
323	Simpler score of routine laboratory tests predicts liver fibrosis in patients with chronic hepatitis B. 2010 , 25, 1569-77		84
322	. 2010 ,		15
321	Transient elastography for the noninvasive assessment of liver fibrosis: a multicentre Canadian study. 2010 , 24, 661-70		46
320	Translational Biomarkers of Acute Drug-Induced Liver Injury: The Current State, Gaps, and Future Opportunities. 2010 , 203-236		2
319	Rare problems associated with the Fontan circulation. 2010 , 20 Suppl 3, 113-9		49
318	Comparison of elastography, serum marker scores, and histology for the assessment of liver fibrosis in hepatitis B virus (HBV)-infected patients in Burkina Faso. 2010 , 82, 454-8		53
317	Assessment of liver fibrosis and cirrhosis by aspartate aminotransferase-to-platelet ratio index in children with biliary atresia. 2010 , 51, 198-202		60
316	Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection. 2010 , 53, 238-44		35
315	Care of hepatitis C virus infection in human immunodeficiency virus-infected patients: modifications in three consecutive large surveys between 2004 and 2009. 2010 , 53, 230-7		10
314	Serum fibrosis markers: death by validation or a leap of faith?. 2010 , 53, 222-4		9
313	The cell biology of hepatitis C virus (HCV) lipid addiction: molecular mechanisms and its potential importance in the clinic. 2010 , 42, 869-79		15
312	Automation of the Hepascore and validation as a biochemical index of liver fibrosis in patients with chronic hepatitis C from the ANRS HC EP 23 Fibrostar cohort. 2010 , 411, 86-91		31
311	Circulating markers of liver fibrosis progression. 2010 , 411, 1009-17		67
310	Non-invasive systems for staging compensated cirrhosis. 2010 , 10, S32-S34		2
309	Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango?. 2010 , 59, 861-6		148
308	Management of nonresponsive hepatitis C. 2010 , 8, 379-95		3

307	Circulating fibronectin isoforms predict the degree of fibrosis in chronic hepatitis C. 2010 , 45, 349-56	29
306	Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. 2010 , 105, 1346-53	114
305	YKL-40 and transient elastography, a powerful team to assess hepatic fibrosis. 2011 , 46, 1369-80	22
304	Post \square FMC-HGE. 2011 ,	
303	Chronic Liver Failure. 2011 ,	2
302	Prediction on liver fibrosis using different APRI thresholds when patient age is a categorical marker in patients with chronic hepatitis B. 2011 , 412, 33-7	14
301	Assessment of new hyaluronic acid assays and their impact on FibroMeter scores. 2011 , 412, 347-52	9
300	[Hepatic elastography. Position paper of the Catalan Society of Gastroenterology]. 2011 , 34, 504-10	4
299	Automated quantification of serum hyaluronic acid for non-invasive assessment of liver fibrosis in chronic hepatic diseases. 2011 , 26, 217-224	1
298	[Evaluation of liver fibrosis by non-invasive methods]. 2011 , 137, 642-4	
297	Noninvasive Alternatives for the Assessment of Liver Fibrosis. 2011 ,	
296	Non-Invasive Diagnostic and Prognostic Evaluation of Liver Cirrhosis and Portal Hypertension. 2011 , 31, 129-138	61
295	Liver stiffness measurement and biochemical markers in Senegalese chronic hepatitis B patients with normal ALT and high viral load. 2011 , 6, e22291	18
294	Usefulness of a novel serum proteome-derived index FI-PRO (fibrosis-protein) in the prediction of fibrosis in chronic hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , 2011 , 23, 701-10	2.2 8
293	Biomarkers of liver fibrosis. 2011 , 26, 802-9	71
292	Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. 2011 , 33, 525-40	215
291	UKHCDO guidelines on the management of HCV in patients with hereditary bleeding disorders 2011. 2011 , 17, e877-83	10
290	Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. 2011 , 18, 23-31	126

289	Reproducibility of liver stiffness measurements in hepatitis C virus (HCV)-infected patients in Egypt. 2011 , 18, e358-65		12
288	A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. 2011 , 8, 53		26
287	Non-invasive index for predicting significant liver fibrosis: comparison of diagnostic performances in patients with chronic hepatitis B and C. 2011 , 56, 555-63		9
286	Invasive and non-invasive methods for the assessment of fibrosis and disease progression in chronic liver disease. 2011 , 25, 291-303		94
285	Non-invasive assessment of liver fibrosis in chronic hepatitis C. 2011 , 5, 625-34		59
284	Non-invasive diagnosis of liver fibrosis. 2011 , 4, 283-291		7
283	Comparison of accuracy of fibrosis degree classifications by liver biopsy and non-invasive tests in chronic hepatitis C. 2011 , 11, 132		18
282	Noninvasive assessment of liver fibrosis. <i>Hepatology</i> , 2011 , 53, 325-35	11.2	278
281	Noninvasive assessment of portal hypertension in patients with cirrhosis. <i>Hepatology</i> , 2011 , 53, 683-94	11.2	104
280	Non-invasive assessment of liver fibrosis: it is time for laboratory medicine. 2011 , 49, 13-32		16
279	The risk of multiplying diagnostic combinations in the absence of a perfect gold standard for a fibrosis test. 2011 , 106, 1853; author reply 1853-4		1
278	A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C. 2011 , 106, 1255-63		73
277	Response to Munteanu et al.. 2011 , 106, 1853-1854		
276	Impact of display alternatives in the determination of bolus handling: a study using high-resolution manometry with impedance. 2011 , 106, 1854-6; author reply 1856-7		5
275	Two or more synchronous combination of noninvasive tests to increase accuracy of liver fibrosis assesment in chronic hepatitis C; results from a cohort of 446 patients. <i>Hepatitis Monthly</i> , 2012 , 12, 177-84	1.8	24
274	Would the physicians eventually obsolete the liver biopsy for the assessment of liver fibrosis?. <i>Hepatitis Monthly</i> , 2012 , 12, 353-4	1.8	4
273	Liver fibrogenesis. 2012 , 102-112.e4		
272	Independent validation of the Enhanced Liver Fibrosis (ELF) score in the ANRS HC EP 23 Fibrostar cohort of patients with chronic hepatitis C. 2012 , 50, 693-9		23

271	SASLT practice guidelines: management of hepatitis C virus infection. 2012 , 18 Suppl, S1-32		5
270	Molecular serum markers of liver fibrosis. 2012 , 7, 105-17		105
269	Serum biomarkers for the non-invasive diagnosis of liver fibrosis: the importance of being validated. 2012 , 50, 595-7		4
268	Diagnosis and evaluation of nonalcoholic fatty liver disease. 2012 , 2012, 145754		145
267	Liver fibrosis in patients with non-alcoholic fatty liver disease: diagnostic options in clinical practice. 2012 , 6, 381-94		8
266	Fibrose h��patique. 2012 , 7, 1-9		
265	Hepatectomy for hepatocellular carcinoma patients with macronodular cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2012 , 24, 575-82	2.2	8
264	Ponction biopsie h��patique : techniques, incidents, accidents. 2012 , 7, 1-10		0
263	[Current trends in liver biopsy indications in chronic liver diseases]. 2012 , 41, 1064-70		4
262	EASL clinical practical guidelines: management of alcoholic liver disease. 2012 , 57, 399-420		489
261	Atherosclerosis risk in HIV-infected patients: the influence of hepatitis C virus co-infection. 2012 , 222, 274-7		36
260	[Serological markers of fibrosis]. 2012 , 35 Suppl 2, 10-6		3
259	Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. 2012 , 56, 55-62		161
258	Development of a novel score for liver fibrosis staging and comparison with eight simple laboratory scores in large numbers of HCV-monoinfected patients. 2012 , 413, 1725-30		18
257	Lect-Hepa, a glyco-marker derived from multiple lectins, as a predictor of liver fibrosis in chronic hepatitis C patients. <i>Hepatology</i> , 2012 , 56, 1448-56	11.2	34
256	Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease. 2012 , 2, 145-55		27
255	Noninvasive methods to assess liver disease in patients with hepatitis B or C. 2012 , 142, 1293-1302.e4		455
254	Biomarkers of Fibrosis and Fibrosis Progression in Chronic Hepatitis C. 2012 , 11, 231-242		

253	[Early detection of chronic liver disease in primary care in the apparently health adult population]. 2012 , 35 Suppl 2, 23-9	1
252	Ultrasonography (US) and non-invasive diagnostic methods for non-alcoholic fatty liver disease (NAFLD) and early vascular damage. Possible application in a population study on the metabolic syndrome (MS). 2012 , 7 Suppl 3, S283-90	5
251	Chronic Hepatitis C Virus. 2012 ,	2
250	Systematic review of the diagnostic performance of serum markers of liver fibrosis in alcoholic liver disease. 2012 , 11, 5	21
249	The osteopontin level in liver, adipose tissue and serum is correlated with fibrosis in patients with alcoholic liver disease. 2012 , 7, e35612	61
248	Noninvasive markers of fibrosis: key concepts for improving accuracy in daily clinical practice. 2012 , 11, 426-439	35
247	Current Trends in Liver Biopsy Indications for Chronic Liver Diseases. 2012 ,	2
246	Serum N-glycomic markers in combination with panels improves the diagnosis of chronic hepatitis B. 2012 , 11, 202-212	9
245	Establishment and validation of a simple noninvasive model to predict significant liver fibrosis in patients with chronic hepatitis B. 2012 , 6, 360-8	8
244	How far is noninvasive assessment of liver fibrosis from replacing liver biopsy in hepatitis C?. 2012 , 19 Suppl 1, 18-32	34
243	Fibrosis progression under maintenance interferon in hepatitis C is better detected by blood test than liver morphometry. 2012 , 19, e143-53	7
242	Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C. 2012 , 35, 92-104	36
241	Non-invasive assessment of liver fibrosis in patients with chronic hepatitis B. 2013 , 7, 356-68	20
240	Élastographie ultrasonore hépatique. 2013 , 94, 531-549	
239	Impact of hepatitis B and delta virus co-infection on liver disease in Mauritania: a cross sectional study. 2013 , 67, 448-57	36
238	Biomarkers of liver fibrosis. 2013 , 62, 33-122	5
237	Non-invasive tests in prediction of liver fibrosis in chronic hepatitis B and comparison with post-antiviral treatment results. 2013 , 37, 152-8	26
236	Markers in nonalcoholic steatohepatitis. 2013 , 61, 67-125	12

235	Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. 2013 , 158, 807-20			238
234	Ultrasound elastography in liver. 2013 , 94, 515-34			124
233	Classification and staging of chronic liver disease from multimodal data. 2013 , 60, 1336-44			27
232	Including osteoprotegerin and collagen IV in a score-based blood test for liver fibrosis increases diagnostic accuracy. 2013 , 415, 63-8			9
231	Prediction of significant fibrosis and cirrhosis in hepatitis B e-antigen negative patients with chronic hepatitis B using routine parameters. 2013 , 43, 441-51			18
230	Study on noninvasive laboratory tests for fibrosis in chronic HBV infection and their evaluation. 2013 , 27, 5-11			17
229	A simple noninvasive index to predict significant liver fibrosis in patients with advanced schistosomiasis japonica. 2013 , 62, 283-8			10
228	Natural History of Chronic HCV Infection and Non-Invasive Assessment of Hepatic Fibrosis. 2013 , 341-352			
227	Noninvasive diagnosis of liver fibrosis and cirrhosis in chronic hepatitis C patients. 2013 , 27, 121-9			9
226	Fontan circulation: success or failure?. 2013 , 29, 811-20			55
225	WITHDRAWN: Noninvasive predictive models of liver fibrosis in patients with chronic hepatitis B. 2013 ,			
224	Transient elastography is a useful noninvasive tool for the evaluation of fibrosis in paediatric chronic liver disease. 2013 , 56, 72-6			92
223	Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection. <i>European Journal of Gastroenterology and Hepatology</i> , 2013 , 25, 1385-95	2.2		3
222	High biological variation of serum hyaluronic acid and Hepascore, a biochemical marker model for the prediction of liver fibrosis. 2013 , 51, 1107-14			14
221	Cutoff values for alcoholic liver fibrosis using magnetic resonance elastography technique. 2013 , 37, 811-7			29
220	Comparative assessment of liver fibrosis by computerized morphometry in naïve patients with chronic hepatitis B and C. <i>Liver International</i> , 2013 , 33, 428-38	7.9		24
219	Liver fibrosis staging through a stepwise analysis of non-invasive markers (FibroSteps) in patients with chronic hepatitis C infection. <i>Liver International</i> , 2013 , 33, 982-90	7.9		16
218	A quantitative stiffness assessment method in liver biopsy teleoperations. 2013 ,			1

217	A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. 2013 , 3, 1065		236
216	Contribution of the ELFG test in algorithms of non-invasive markers towards the diagnosis of significant fibrosis in chronic hepatitis C. 2013 , 8, e59088		11
215	Serum ceruloplasmin levels correlate negatively with liver fibrosis in males with chronic hepatitis B: a new noninvasive model for predicting liver fibrosis in HBV-related liver disease. 2013 , 8, e77942		17
214	Clinical Application of Non-Invasive Markers of Liver Fibrosis. 2013 ,		2
213	A novel fibrosis index comprising a non-cholesterol sterol accurately predicts HCV-related liver cirrhosis. 2014 , 9, e93601		4
212	Noninvasive Biomarkers of Liver Fibrosis: An Overview. 2014 , 2014, 1-15		36
211	Invasive and non-invasive diagnosis of cirrhosis and portal hypertension. <i>World Journal of Gastroenterology</i> , 2014 , 20, 4300-15	5.6	69
210	Non invasive tools for the diagnosis of liver cirrhosis. <i>World Journal of Gastroenterology</i> , 2014 , 20, 18131-50	5.6	57
209	Liver fibrosis markers in alcoholic liver disease. <i>World Journal of Gastroenterology</i> , 2014 , 20, 8018-23	5.6	33
208	Lect-Hepa facilitates estimating treatment outcome during interferon therapy in chronic hepatitis C patients. 2014 , 11, 44		1
207	Impact of contacting study authors to obtain additional data for systematic reviews: diagnostic accuracy studies for hepatic fibrosis. 2014 , 3, 107		36
206	CUFA algorithm: assessment of liver fibrosis using routine laboratory data. 2014 , 21, 956-64		3
205	TIMP-1 in patients with cirrhosis: relation to liver dysfunction, portal hypertension, and hemodynamic changes. 2014 , 49, 1103-10		20
204	Non-invasive diagnosis of liver fibrosis in chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2014 , 20, 2854-66	5.6	52
203	Correlation of biochemical markers and HCV RNA titers with fibrosis stages and grades in chronic HCV-3a patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2014 , 26, 788-94	2.2	9
202	Chronic hepatitis C and liver fibrosis. <i>World Journal of Gastroenterology</i> , 2014 , 20, 11033-53	5.6	130
201	An Increased Ratio of Glycated Albumin to HbA1c Is Associated with the Degree of Liver Fibrosis in Hepatitis B Virus-Positive Patients. 2014 , 2014, 351396		6
200	Comparison of Fibrotest and PGAA for the diagnosis of fibrosis stage in patients with alcoholic liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2014 , 26, 404-11	2.2	12

199	HIV/hepatitis C virus-coinfected patients and cirrhosis: how to diagnose it and what to do next?. 2014 , 58, 840-7			6
198	New Tools for the Noninvasive Assessment of Cirrhosis. 2014 ,			2
197	[Prognosis assessment of alcoholic liver disease: how and why?]. 2014 , 43, 124-34			3
196	An analysis on force data during biopsy insertion. 2014 ,			1
195	Prospective evaluation of FibroTest [®] , FibroMeter [®] , and HepaScore [®] for staging liver fibrosis in chronic hepatitis B: comparison with hepatitis C. 2014 , 61, 28-34			56
194	Non-invasive liver fibrosis score calculated by combination of virtual touch tissue quantification and serum liver functional tests in chronic hepatitis C patients. 2014 , 44, 280-7			14
193	Usefulness of indirect noninvasive methods in predicting progression to cirrhosis in chronic hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , 2015 , 27, 826-33	2.2		3
192	Aspartate aminotransferase to platelet ratio index as a prospective predictor of hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. 2015 , 30, 131-138			28
191	Assessing liver disease in HIV-HCV coinfectd patients. 2015 , 10, 316-22			8
190	Novel α -macroglobulin cleaved fragments as biomarkers of early liver fibrosis in patients with chronic hepatitis C. 2015 , 10, 5-16			
189	. 2015 ,			
188	General assessment and management. 2015 , 135-146			
187	Non invasive assessment of liver fibrosis in chronic hemodialysis patients with viral hepatitis C. 2015 , 22, 273			2
186	Liver fibrosis markers of nonalcoholic steatohepatitis. <i>World Journal of Gastroenterology</i> , 2015 , 21, 7427-35	5.6		33
185	Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease. <i>World Journal of Gastroenterology</i> , 2015 , 21, 11044-52	5.6		22
184	Non-invasive diagnosis of liver fibrosis and cirrhosis. <i>World Journal of Gastroenterology</i> , 2015 , 21, 11567-73	5.6		151
183	A new metabolism-related index correlates with the degree of liver fibrosis in hepatitis C virus-positive patients. 2015 , 2015, 926169			2
182	Diagnosis and Management of Alcoholic Liver Disease. 2015 , 3, 109-16			44

181	Biomarkers in HCV Infection. 2015 , 70, 131-96		1
180	EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. 2015 , 63, 237-64		1082
179	Diagnosis of liver fibrosis: present and future. 2015 , 35, 166-83		38
178	Non-invasive evaluation of liver fibrosis: More well-validated tests available for patient management. <i>Liver International</i> , 2015 , 35, 1643-5	7.9	3
177	Ultrasound elastography: liver. 2015 , 40, 698-708		17
176	Non-invasive diagnosis tests. 2015 , 53-62		
175	Noninvasive evaluation of liver fibrosis using real-time tissue elastography and transient elastography (FibroScan). 2015 , 34, 403-10		26
174	Current drugs in early development for treating hepatitis C virus-related hepatic fibrosis. 2015 , 24, 1229-39		21
173	Noninvasive Assessment of Liver Fibrosis. 2015 , 33, 498-503		40
172	Screening for significant chronic liver disease by using three simple ultrasound parameters. 2015 , 84, 1466-1472		4
171	von Willebrand factor as a novel noninvasive predictor of portal hypertension and esophageal varices in hepatitis B patients with cirrhosis. 2015 , 50, 1160-9		14
170	Noninvasive Markers of Fibrosis in the Assessment of Cirrhosis. 2015 , 39-47		
169	Comparison of noninvasive scores for the detection of advanced fibrosis in patients with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2015 , 27, 137-41	2.2	27
168	High liver fibrosis index FIB-4 is highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers. <i>Hepatology</i> , 2015 , 61, 1261-8	11.2	67
167	Enhanced liver fibrosis panel as a predictor of liver fibrosis in chronic hepatitis C patients. 2015 , 49, 235-41		29
166	Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease. 2015 , 35, 291-303		56
165	Assessment of Substantial Liver Fibrosis by Real-time Shear Wave Elastography in Methotrexate-Treated Patients With Rheumatoid Arthritis. 2015 , 34, 1621-30		13
164	Biomarcadores, índices y algoritmos para el diagnóstico de fibrosis hepática en pacientes con hepatitis crónica por virus C. 2015 , 8, 179-187		

163	Contemporary assessment of hepatic fibrosis. 2015 , 19, 123-34	22
162	An HCC Aggressiveness Index and Blood GTP, Bilirubin and Platelet Levels. 2016 , 5,	6
161	Transient elastography and APRI score: looking at false positives and false negatives. Diagnostic performance and association to fibrosis staging in chronic hepatitis C. 2016 , 49, e5432	8
160	Serum Liver Fibrosis Markers in the Prognosis of Liver Cirrhosis: A Prospective Observational Study. 2016 , 22, 2720-30	5
159	New Concepts on Pathogenesis and Diagnosis of Liver Fibrosis; A Review Article. 2016 , 8, 166-178	29
158	Evaluation of the biomarker candidate MFAP4 for non-invasive assessment of hepatic fibrosis in hepatitis C patients. 2016 , 14, 201	27
157	Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy?. 2016 , 7, 159	42
156	Automatic detection of cirrhosis in hospitalized patients: a pragmatic experience. <i>European Journal of Gastroenterology and Hepatology</i> , 2016 , 28, 74-81	2.2
155	Prevalence and Risk Factors of Diabetes Mellitus in Patients with Autoimmune Hepatitis. 2016 , 55, 879-85	4
154	Hyaluronic acid algorithm-based models for assessment of liver fibrosis: translation from basic science to clinical application. 2016 , 15, 131-40	1
153	Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. 2016 , 65, 570-8	213
152	Elastography of Diffuse Liver Diseases. 2016 , 51, 358-366	5
151	Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV. 2016 , 13, 279-88	10
150	Comparative analysis of the serum proteome for biomarker discovery to reveal hepatotoxicity induced by iron ion radiation in mice. 2016 , 167, 57-66	3
149	Hepatic Fibrosis in Hepatitis C. 2016 , 79-108	
148	Major changes in the number and indications of liver biopsy for chronic liver diseases over one decade in France. <i>European Journal of Gastroenterology and Hepatology</i> , 2016 , 28, e26-32	2.2 6
147	Liver resection for cancer: New developments in prediction, prevention and management of postresectional liver failure. 2016 , 65, 1217-1231	56
146	Liver Fibrosis Evaluation Using Real-time Shear Wave Elastography in Hepatitis C-Monoinfected and Human Immunodeficiency Virus/Hepatitis C-Coinfected Patients. 2016 , 35, 1299-308	13

145	Reference Intervals of Fibrosis Index Based on Four Indicators in Healthy Elderly Chinese. 2016 , 30, 645-8	2
144	AST to Platelet Ratio Index Predicts Mortality in Hospitalized Patients With Hepatitis B-Related Decompensated Cirrhosis. 2016 , 95, e2946	6
143	Diagnostic Approaches and Clinical End Points of Treatment in Alcoholic Liver Disease. 2016 , 195-209	1
142	Changes in Noninvasive Liver Fibrosis Indices and Spleen Size During Chemotherapy: Potential Markers for Oxaliplatin-Induced Sinusoidal Obstruction Syndrome. 2016 , 95, e2454	15
141	Liver Fibrosis and Its Assessment. 2016 , 43-52	
140	Utility of Noninvasive Markers of Fibrosis in Cholestatic Liver Diseases. 2016 , 20, 143-58	14
139	A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis. 2017 , 66, 1158-1165	56
138	Liver fibrogenesis. 2017 , 110-122.e5	
137	Liver Disease and Fibrosis Assessment in Substance Use-Related Disorders. 2017 , 6, 164-168	3
136	Assessment of liver fibrosis in chronic hepatitis B via multimodal data. 2017 , 253, 169-176	5
135	Prediction of long-term clinical outcome in a diverse chronic hepatitis B population: Role of the PAGE-B score. 2017 , 24, 1023-1031	15
134	A Single Test Combining Blood Markers and Elastography is More Accurate Than Other Fibrosis Tests in the Main Causes of Chronic Liver Diseases. 2017 , 51, 639-649	20
133	A Metabolomics Signature Linked To Liver Fibrosis In The Serum Of Transplanted Hepatitis C Patients. 2017 , 7, 10497	16
132	Wet Biomarker-Based Assessment of Steatosis, Inflammation, and Fibrosis in NAFLD. 2017 , 16, 308-316	
131	Study of Some Serum Biochemical Markers of Liver Fibrosis in Patients with Chronic HCV. 2017 , 01,	1
130	Noninvasive Diagnostic and Prognostic Assessment Tools for Liver Fibrosis and Cirrhosis in Patients with Chronic Liver Disease. 2017 ,	2
129	Quantitative Elastography Methods in Liver Disease: Current Evidence and Future Directions. 2018 , 286, 738-763	145
128	A single blood test adjusted for different liver fibrosis targets improves fibrosis staging and especially cirrhosis diagnosis. 2018 , 2, 455-466	3

127	Non-invasive Assessment of Liver Disease. 2018 , 163-179	
126	Decreased Taurine and Creatine in the Thalamus May Relate to Behavioral Impairments in Ethanol-Fed Mice: A Pilot Study of Proton Magnetic Resonance Spectroscopy. 2018 , 17, 1536012117749051	8
125	Hepatitis B Virus and Liver Disease. 2018 ,	1
124	Prospects in non-invasive assessment of liver fibrosis: Liquid biopsy as the future gold standard?. 2018 , 1864, 1024-1036	29
123	Diagnostic Methods for Cirrhosis and Portal Hypertension. 2018 ,	1
122	Markers of hepatic fibrosis. 2018 , 150, 310-316	
121	Invasive and non-invasive assessment of portal hypertension. 2018 , 12, 44-55	31
120	A noninvasive diagnosis of hepatic fibrosis by BioFibroScore [®] in chronic hepatitis C patients. 2018 , 33, 291-297	11
119	Diagnostic accuracy of the Coopscore to predict liver fibrosis in human immunodeficiency virus/hepatitis B virus co-infection. 2018 , 55, 236-243	1
118	Utility of diffusion weighted imaging (DWI) in assessment of liver fibrosisPeer review under responsibility of Alexandria University Faculty of Medicine.View all notesAvailable online 9 October 2017View all notes. 2018 , 54, 347-352	1
117	Pitfalls in the non-invasive assessment of liver fibrosis with eLIFT-FM algorithm. 2018 , 68, 602-603	
116	Markers of hepatic fibrosis. 2018 , 150, 310-316	7
115	Serum Interleukin-8, Osteopontin, and Monocyte Chemoattractant Protein 1 Are Associated With Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. 2018 , 2, 1344-1355	34
114	The enhanced liver fibrosis (ELF) test in diagnosis and management of liver fibrosis. 2018 , 79, 694-699	8
113	Doppler ultrasonography devices, including elastography, allow for accurate diagnosis of severe liver fibrosis. 2018 , 108, 133-139	3
112	Non-invasive Fibrosis Testing in Patients with Chronic Hepatitis B. 2018 , 17, 492-501	1
111	CT texture analysis of the liver for assessing hepatic fibrosis in patients with hepatitis C virus. 2019 , 92, 20180153	20
110	Multidetector Computed Tomography for Retrospective, Noninvasive Staging of Liver Fibrosis. 2018 , 47, 569-584	12

109	Non-invasive Assessment of Fibrosis and Cirrhosis. 2018 , 93-106	
108	Routine indexes for cirrhosis and significant fibrosis detection in patients with compensated chronic hepatitis B. 2019 , 51, 127-134	2
107	Thiamine and phosphate esters concentrations in whole blood and serum of patients with alcohol use disorder: a relation with cognitive deficits. 2021 , 24, 530-541	4
106	Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH). 2019 , 8,	64
105	Nichtinvasive Diagnostik bei nichtalkoholischer Fettlebererkrankung (NAFLD). 2019 , 17, 75-81	
104	Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date. 2019 , 33, 451-463	8
103	Comparison of liver stiffness assessment by transient elastography and shear wave elastography using six ultrasound devices. 2019 , 49, 676-686	21
102	Special Treatment Considerations for Wilson Disease. 2019 , 235-245	0
101	Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities. 2019 , 79, 903-927	22
100	Non-invasive assessment of liver fibrosis and prognosis: an update on serum and elastography markers. 2019 , 13, 361-374	44
99	Noninvasive Tests of Liver Fibrosis. 2019 , 445-453	
98	Derivation and Performance of Standardized Enhanced Liver Fibrosis (ELF) Test Thresholds for the Detection and Prognosis of Liver Fibrosis. 2019 , 3, 815-826	14
97	Chronic hepatitis C infection - Noninvasive assessment of liver fibrosis in the era of direct acting antivirals. 2019 , 51, 183-189	10
96	Assessment of liver fibrosis by transient elastography (Fibroscan) in patients with A1AT deficiency. 2019 , 43, 77-81	11
95	Validation of the fibrosis-4 (FIB-4) index in the diagnosis of liver disease of rheumatoid arthritis patients treated with methotrexate. 2019 , 29, 936-942	6
94	Noninvasive methods of classification and staging of chronic hepatic diseases. 2020 , 30, 358-366	
93	Detecting liver fibrosis using a machine learning-based approach to the quantification of the heart-induced deformation in tagged MR images. 2020 , 33, e4215	8
92	Non-invasive fibrosis tests to predict complications in compensated post-hepatitis C cirrhosis. 2020 , 44, 524-531	2

91	Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting. 2020 , 69, 764-780	39
90	The role of noninvasive biomarkers in diagnosis and risk stratification in nonalcoholic fatty liver disease. 2020 , 3, e00127	4
89	Identifying High-Risk NASH Patients: What We Know so Far. 2020 , 12, 125-138	11
88	Consensus on the diagnosis and treatment of hepatic fibrosis (2019). 2020 , 21, 127-138	4
87	A pragmatic non-invasive assessment of liver fibrosis in patients with psoriasis, rheumatoid arthritis or Crohn's disease receiving methotrexate therapy. 2020 , 44S, 100003	1
86	Limitations of non-invasive tests for assessment of liver fibrosis. 2020 , 2, 100067	54
85	Alcohol associated liver disease 2020: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). 2020 , 52, 374-391	15
84	Obstructive sleep apnea and nonalcoholic fatty liver disease: do we need to consider this association in current clinical practice?. 2021 , 77, 355-356	1
83	Non-selective beta-blockers increase overall and liver mortality in alcoholic cirrhosis with MELD \geq 2 over 5 years of follow-up. <i>Liver International</i> , 2021 , 41, 168-179	7.9 1
82	Chronic Hepatitis B Virus Infection: Noninvasive Assessment of Liver Disease. 2021 , 251-266	
81	Assessment of Liver Disease Severity. 2021 , 1-20	
80	Valoraci3n bioqu3mica en la enfermedad hep3tica grasa asociada a la disfunci3n metab3lica. 2021 , 2, 209-219	
79	Treatment of hepatitis C virus infection with direct-acting antivirals plus ribavirin eliminates viral RNA from peripheral blood mononuclear cells and reduces virologic relapse in diverse hepatic parenchymal changes. 2021 , 166, 1071-1081	1
78	Biochemical assessment of metabolic associated fatty liver disease. 2021 , 2, 199-208	1
77	The FIB-4 Index Is a Useful Predictor for the Development of Hepatocellular Carcinoma in Patients with Coexisting Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B. 2021 , 13,	2
76	FibroTest for Evaluating Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-Analysis. 2021 , 10,	5
75	EASL-ALEH 2015 algorithm for the use of transient elastography in treatment-naive patients with hepatitis B: An independent validation. 2021 , 28, 1169-1176	1
74	Systematic Review with Meta-Analyses: Diagnostic Accuracy of FibroMeter Tests in Patients with Non-Alcoholic Fatty Liver Disease. 2021 , 10,	3

73	Role of inflammation in alcohol-related brain abnormalities: a translational study. 2021 , 3, fcab154		1
72	Nonalcoholic fatty liver disease: use of diagnostic biomarkers and modalities in clinical practice. 2021 , 21, 1065-1078		1
71	Liver Biopsy. 2010 , 762-770		0
70	Non-invasive Serum Markers of Fibrosis. 2018 , 63-82		1
69	Non-invasive testing for liver pathology in alpha-1 antitrypsin deficiency. 2020 , 7,		1
68	A new model using routinely available clinical parameters to predict significant liver fibrosis in chronic hepatitis B. 2011 , 6, e23077		61
67	Angiopoietin-2 Serum Levels Improve Noninvasive Fibrosis Staging in Chronic Hepatitis C: A Fibrogenic-Angiogenic Link. 2013 , 8, e66143		9
66	Liver stiffness by transient elastography predicts liver-related complications and mortality in patients with chronic liver disease. 2014 , 9, e95776		81
65	Predictive Ability of Laboratory Indices for Liver Fibrosis in Patients with Chronic Hepatitis C after the Eradication of Hepatitis C Virus. 2015 , 10, e0133515		19
64	Clinical and Biological Risk Factors for Neuropsychological Impairment in Alcohol Use Disorder. 2016 , 11, e0159616		14
63	Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease. 2017 , 5, 261-271		30
62	Development and validation of a model for staging hepatic fibrosis for chronic hepatitis B patients with E antigen-positive. 2017 , 8, 98812-98822		2
61	Evaluation of liver fibrosis: "Something old, something new". <i>Annals of Gastroenterology</i> , 2016 , 29, 445-453	2.2	31
60	Serum Marker Panels for Predicting Liver Fibrosis - An Update. <i>Clinical Biochemist Reviews</i> , 2020 , 41, 67-73		1
59	[The usefulness of transient elastography to diagnose cirrhosis in patients with alcoholic liver disease]. 2009 , 15, 42-51		29
58	Hepatocellular carcinoma in patients with hepatitis C virus-related chronic liver disease. <i>World Journal of Gastroenterology</i> , 2007 , 13, 2455-60	5.6	26
57	A specific gene-expression signature quantifies the degree of hepatic fibrosis in patients with chronic liver disease. <i>World Journal of Gastroenterology</i> , 2007 , 13, 383-90	5.6	10
56	Noninvasive diagnosis of hepatic fibrosis in chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2007 , 13, 4287-94	5.6	34

55	Staging of liver fibrosis in chronic hepatitis B patients with a composite predictive model: a comparative study. <i>World Journal of Gastroenterology</i> , 2010 , 16, 501-7	5.6	39
54	Checkmate to liver biopsy in chronic hepatitis C?. <i>World Journal of Gastroenterology</i> , 2012 , 18, 5514-20	5.6	13
53	Routine blood tests to predict liver fibrosis in chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2012 , 18, 746-53	5.6	26
52	Tools for the diagnosis of hepatitis C virus infection and hepatic fibrosis staging. <i>World Journal of Gastroenterology</i> , 2014 , 20, 3431-42	5.6	30
51	Noninvasive assessment of liver fibrosis in patients with chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2014 , 20, 12031-8	5.6	19
50	Non-invasive diagnosis of alcoholic liver disease. <i>World Journal of Gastroenterology</i> , 2014 , 20, 14626-41	5.6	80
49	Biomarkers in nonalcoholic fatty liver disease-the emperor has no clothes?. <i>World Journal of Gastroenterology</i> , 2015 , 21, 3223-31	5.6	25
48	Chronic hepatitis C virus infection: Serum biomarkers in predicting liver damage. <i>World Journal of Gastroenterology</i> , 2016 , 22, 1367-81	5.6	21
47	Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness. <i>World Journal of Gastroenterology</i> , 2016 , 22, 1711-20	5.6	46
46	Liver fibrosis indices for identifying patients at low risk of developing hepatocellular carcinoma after eradication of HCV. <i>Antiviral Therapy</i> , 2017 , 22, 185-193	1.6	8
45	Ultrasound shear wave elastography and liver biopsy to determine liver fibrosis in adult patients. <i>Journal of Family Medicine and Primary Care</i> , 2020 , 9, 943-949	1.5	2
44	The combination of endoglin and FIB-4 increases the accuracy of detection of hepatic fibrosis in chronic hepatitis C patients. <i>Open Journal of Gastroenterology</i> , 2012 , 02, 62-67	0.2	1
43	Elevation of the glycated albumin to glycated hemoglobin ratio during the progression of hepatitis C virus related liver fibrosis. <i>World Journal of Hepatology</i> , 2012 , 4, 11-7	3.4	13
42	Two or More Synchronous Combination of Noninvasive Tests to Increase Accuracy of Liver Fibrosis Assessment in Chronic Hepatitis C; Results From a Cohort of 446 Patients. <i>Hepatitis Monthly</i> , 2012 , 12, 177-184	1.8	20
41	Recent advances in hepatitis C virus research and understanding the biology of the virus. <i>World Journal of Gastroenterology</i> , 2007 , 13, 2404-5	5.6	2
40	Évaluer la fibrose: Pourquoi? Comment? Pour qui?. 2010 , 245-257		
39	Non-Histological Assessment of Liver Fibrosis. 2010 , 554-561		
38	Alcoholic Liver Disease. 2010 , 465-474		

37	Assessment of Liver Function in Clinical Practice. 2011 , 47-76		3
36	Que reste-t-il des indications de la ponction biopsie hépatique?. 2011 , 231-237		
35	Assessing the Progression of Chronic HCV to Cirrhosis. 2012 , 21-33		
34	Relationship between hepatic histopathological progression and findings of clinical noninvasive examination in patients with non-viral liver diseases. <i>Academic Journal of Second Military Medical University</i> , 2011 , 31, 830-835		
33	Non-Invasive Liver Assessment. 1042-1045		
32	Pentraxin 3 (PTX3) as a Biomarker of Liver Disease. <i>Biomarkers in Disease</i> , 2017 , 603-621		2
31	Hepascore and Its Application to Liver Disease. <i>Biomarkers in Disease</i> , 2017 , 23-45		
30	Acoustic Radiation Force Impulse Elastometry (ARFI Elastometry) in Chronic Viral Hepatitis. <i>Medical Visualization</i> , 2017 , 82-93	0.2	
29	Liver Cirrhosis with Steatohepatitis: Nonalcoholic Steatohepatitis and Alcoholic Steatohepatitis. 2019 , 1-21		
28	Fibrosis Assessment via Liver Stiffness Measurements: How Many Patients Are Spared from a Liver Biopsy?. 2020 , 563-588		
27	Noninvasive Biomarkers for Liver Fibrosis. 2020 , 427-441		
26	Non-Invasive Markers of Liver Fibrosis in Children with Chronic Hepatic Disorders. <i>Gene, Cell and Tissue</i> , 2020 , 7,	0.6	
25	Biomarkers of liver fibrosis. 155-162		
24	Clinical evaluation of disease progression in chronic liver disease: towards an integrated system?. 163-172		
23	Assessing liver fibrosis with serum marker models. <i>Clinical Biochemist Reviews</i> , 2007 , 28, 3-10	7.3	32
22	The treatment of hepatic encephalopathy in the cirrhotic patient. <i>Gastroenterology and Hepatology</i> , 2010 , 6, 1-12	0.7	1
21	Prognostic value of liver fibrosis biomarkers: a meta-analysis. <i>Gastroenterology and Hepatology</i> , 2011 , 7, 445-54	0.7	28
20	A comparative study of non-invasive methods for fibrosis assessment in chronic HCV infection. <i>Hepatitis Monthly</i> , 2010 , 10, 88-94	1.8	27

19	Non-invasive assessment of liver fibrosis. <i>Annals of Gastroenterology</i> , 2012 , 25, 218-231	2.2	75
18	Hepatitis C screening. <i>Ochsner Journal</i> , 2014 , 14, 664-8	1.5	8
17	Noninvasive predictive models of liver fibrosis in patients with chronic hepatitis B. <i>International Journal of Clinical and Experimental Medicine</i> , 2015 , 8, 961-71		5
16	Noninvasive biomarkers FibroTest and ActiTest versus liver biopsy in chronic hepatitis C patients: the Middle East experience. <i>Annals of Gastroenterology</i> , 2015 , 28, 265-270	2.2	3
15	[Delta hepatitis: Epidemiology, diagnostic, natural history and treatment]. <i>Revue De Medecine Interne</i> , 2021 ,	0.1	
14	[Evaluation of the Validity of ROI Setting in CEI Used for the Assessment of Liver].. <i>Japanese Journal of Radiological Technology</i> , 2022 , 78, 44-52		0
13	Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches.. <i>Diagnostics</i> , 2022 , 12,	3.8	2
12	Prospective screening for significant liver fibrosis by fibrosis-4 in primary care patients without known liver disease.. <i>European Journal of Gastroenterology and Hepatology</i> , 2021 , 33,	2.2	0
11	Management of alcohol-related liver disease: the French Association for the Study of the Liver and the French Alcohol Society clinical guidelines.. <i>Liver International</i> , 2022 ,	7.9	0
10	Effect of Antiviral Treatment on Serum Markers of Liver Fibrosis in HIV/Hepatitis C virus-Coinfected Patients: The Fibrovic 2 Study [ANRS HC02. <i>Antiviral Therapy</i> , 2009 , 14, 211-219	1.6	19
9	Non-invasive diagnosis and staging of non-alcoholic fatty liver disease. <i>Hormones</i> ,	3.1	0
8	Serum biomarkers for liver fibrosis. 2022 ,		0
7	Leberfibrose - Diagnostik und innovative Therapieansätze. 2022 , 9, 40-50		0
6	Prognostic Factors for Overall Survival in Patients with HCV-Related HCC Undergoing Molecular Targeted Therapies: Beyond a Sustained Virological Response. 2022 , 14, 4850		0
5	Epidemiology, natural history, and diagnosis of metabolic dysfunction-associated fatty liver disease: a comparative review with nonalcoholic fatty liver disease. 2022 , 13, 204201882211396		0
4	A Nomogram for Predicting Prognosis of Advanced Schistosomiasis japonica in Dongzhi County: A Case Study. 2023 , 8, 33		0
3	Engineering At-Home Dilution and Filtration Methods to Enable Paper-Based Colorimetric Biosensing in Human Blood with Cell-Free Protein Synthesis. 2023 , 13, 104		0
2	Liver fibrosis for the dermatologist: a review.		0

1 Screening for Liver Fibrosis in the General Population: Where Do We Stand in 2022?. **2023**, 13, 91 o